ArticleCell death and differentiation2026
TAB2 controls a TAK1-independent cell death checkpoint at the level of TNFR1 complex II in the TNF pathway.
Article in Cell death and differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- TAB2 Causes Neuronal Damage by Aggravating Microglia-Mediated Neuroinflammation in Parkinson's Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- [Menstrual blood-derived mesenchymal stem cell transplantation improves anti-fibrosis mechanisms in mouse models of alcoholic liver fibrosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- Regulated cell death in cancer: Mechanisms, crosstalk, and opportunities for therapy.Cancer letters · 2025Review
- Danggui Buxue Decoction attenuates 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung cancer growth in A/J mice by suppressing HIF-1α/VEGF-mediated angiogenesis.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Tumor necrosis factor (TNF) signaling determines the cell's fate by promoting either survival or cell death via apoptosis, necroptosis or pyroptosis. Excessive or chronic cell death by TNF was shown to drive inflammatory pathologies, highlighting the importance of the mechanisms that normally block TNF cytotoxicity. This study investigates the role of TAB2, an adaptor protein traditionally linked to TAK1 activation in the TNF pathway. Contrary to expectations, TAB2 deficiency did not impair TAK1-dependent NF-κB or MAPK signaling, nor did it affect TAK1- and IKK-dependent inhibitory phosphorylation of RIPK1 in TNFR1 complex I, indicating that TAK1 remains functional in absence of TAB2. Still, TAB2 deficiency switches the TNF response from survival to apoptosis, demonstrating a crucial TAK1-independent pro-survival function of TAB2 in the pathway. This switch was absent in TAB3-deficient conditions, highlighting a non-redundant function of TAB2. We show that TAB2 is an integral part of TNFR1 complex II, limiting the abundance of the cytotoxic complex through direct association. The ubiquitin-binding NZF domain of TAB2 is critical for this function as cells expressing a NZF-deficient mutant switched the TNF response towards apoptosis, while not affecting TAK1-mediated signaling. Moreover, we found that the NZF domain of TAB2 also represses TNF-mediated necroptosis in conditions of Caspase-8 inhibition, thereby showing that TAB2 represses two different cell death modalities in the TNF pathway by limiting the abundance of two variations of the cytotoxic complex II. Together, our results reveal the existence of a new cell death checkpoint in the TNF pathway that is controlled by TAB2, through a mechanism independent of its established function in TAK1 recruitment and activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.